Home » Stocks » NKTX

Nkarta, Inc. (NKTX)

Stock Price: $34.26 USD 0.98 (2.94%)
Updated December 1, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 1.12B
Revenue (ttm) 385
Net Income (ttm) n/a
Shares Out 32.60M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 1
Last Price $34.26
Previous Close $33.28
Change ($) 0.98
Change (%) 2.94%
Day's Open 33.61
Day's Range 32.83 - 36.76
Day's Volume 141,771
52-Week Range 23.52 - 47.90

More Stats

Market Cap 1.12B
Enterprise Value 795.68M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 32.60M
Float n/a
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 967,582
Short Ratio 4.51
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 2,900,567.02
PB Ratio 3.30
Revenue 385
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 321.04M
Net Cash / Share 9.85
Gross Margin -4,441,966.23%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(26.47% upside)
Current: $34.26
Target: 43.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-98.24%-
Gross Profit0.126.55
Operating Income-22.35-0.36
Net Income-21.08-0.27
Shares Outstanding1.461.06
Earnings Per Share-14.41-0.26
Operating Cash Flow-18.37-5.18
Capital Expenditures-1.93-0.76
Free Cash Flow-20.30-5.94
Cash & Equivalents37.267.96
Total Debt7.30-
Net Cash / Debt29.967.96
Book Value-25.48-5.40
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Nkarta, Inc.
Country United States
CEO Paul J. Hastings

Stock Information

Ticker Symbol NKTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NKTX
IPO Date July 10, 2020


Nkarta, a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates are NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded in 2015 and is headquartered in South San Francisco, California.